A Phase 3 interventional study of ITI-007 and Risperidone in Schizophrenia, sponsored by Intra-Cellular Therapies, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-10-02.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.
Among the 12 studies testing lumateperone in Schizophrenia, this one has the largest enrollment, is the only one that started in 2015, is one of 5 in phase 3, and was the 4th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
University of Massachusetts, Worcester · Sites in United States
Ages 18–65
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lumateperone is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 696 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Intra-Cellular Therapies, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 12th largest by enrollment of the 176 interventional ones that give a count, is one of 6 that started in 2015, is one of 74 in phase 3, and was the 187th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing lumateperone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT06174116University of Massachusetts, WorcesterMetabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing lumateperone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lumateperone 14 mg (ITI-007 20 mg Tosylate) administered orally as formulated capsules once daily for 6 weeks
Drug: ITI-007
Lumateperone 42 mg (ITI-007 60 mg Tosylate) administered orally as formulated capsules once daily for 6 weeks
Drug: ITI-007
Placebo administered orally as visually-matched capsules once daily for 6 weeks
Drug: Placebo
Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks
Drug: Risperidone
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
Time frame: 6 weeks
Change From Baseline to Week 6 in Clinical Global Impressions-Severity of Illness Scale
The Clinical Global Impressions (CGI) Scale is a standardized assessment tool that the clinician can use to rate the severity of illness, change over time, and efficacy of medication, taking into account the subject's clinical condition and the severity of side effects. The CGI Scale consists of 3 global subscales, only one of which was used in the present study. The first subscale, Severity of Illness (CGI-S), assesses the clinician's impression of the subject's current illness state; it is often used both before and after treatment. Scores on the Severity of Illness subscale range from 1 = "not ill" at all to 7 = "among the most extremely ill."
Time frame: 6 weeks
| Milestone | Lumateperone 14 mg (ITI-007 20 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Risperidone |
|---|---|---|---|---|
| Started | 174 | 174 | 174 | 174 |
| Completed | 113 | 128 | 133 | 105 |
| Not completed | 61 | 46 | 41 | 69 |
| Withdrew: Adverse event | 6 | 0 | 1 | 10 |
| Withdrew: Lack of efficacy | 13 | 10 | 10 | 8 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 5 | 2 | 7 | 2 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 34 | 30 | 20 | 37 |
| Withdrew: Other | 3 | 3 | 2 | 10 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 |
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
| units on a scale | Lumateperone 14 mg (ITI-007 20 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Risperidone |
|---|---|---|---|---|
| Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score | -15.0 ± 1.27 | -14.6 ± 1.23 | -15.1 ± 1.21 | -20.5 ± 1.33 |
The Clinical Global Impressions (CGI) Scale is a standardized assessment tool that the clinician can use to rate the severity of illness, change over time, and efficacy of medication, taking into account the subject's clinical condition and the severity of side effects. The CGI Scale consists of 3 global subscales, only one of which was used in the present study. The first subscale, Severity of Illness (CGI-S), assesses the clinician's impression of the subject's current illness state; it is often used both before and after treatment. Scores on the Severity of Illness subscale range from 1 = "not ill" at all to 7 = "among the most extremely ill."
Results for this outcome have not been posted.
Collected over From signing ICF until end of study procedures (~10 weeks), including 6 weeks of double blind treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lumateperone 14 mg (ITI-007 20 mg Tosylate) | 0/172 (0%) | 0/172 (0%) | 57/172 (33.1%) |
| Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 0/172 (0%) | 1/172 (0.6%) | 76/172 (44.2%) |
| Placebo | 0/178 (0%) | 0/178 (0%) | 68/178 (38.2%) |
| Risperidone | 1/173 (0.6%) | 0/173 (0%) | 79/173 (45.7%) |
| Event | Lumateperone 14 mg (ITI-007 20 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Risperidone |
|---|---|---|---|---|
| AgitationPsychiatric disorders | 0/172 | 1/172 | 0/178 | 0/173 |
| Event | Lumateperone 14 mg (ITI-007 20 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Risperidone |
|---|---|---|---|---|
| HeadacheNervous system disorders | 16/172 | 36/172 | 25/178 | 36/173 |
| SomnolenceNervous system disorders | 19/172 | 31/172 | 11/178 | 30/173 |
| ConstipationGastrointestinal disorders | 10/172 | 12/172 | 17/178 | 7/173 |
| NauseaGastrointestinal disorders | 7/172 | 16/172 | 8/178 | 15/173 |
| SedationNervous system disorders | 11/172 | 7/172 | 5/178 | 14/173 |
| Weight IncreasedInvestigations | 5/172 | 3/172 | 4/178 | 11/173 |
| ToothacheGastrointestinal disorders | 5/172 | 7/172 | 11/178 | 8/173 |
| DyspepsiaGastrointestinal disorders | 6/172 | 9/172 | 10/178 | 3/173 |
| Dry MouthGastrointestinal disorders | 4/172 | 9/172 | 0/178 | 7/173 |
4 subjects received an incorrect treatment compared to that which they were randomized. The numbers presented in Baseline Characteristics are as treated in each group except as noted.
| Age, Continuous(years) | Lumateperone 14 mg (ITI-007 20 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Risperidone | Total |
|---|---|---|---|---|---|
| Mean | 42.7 ± 9.99 | 41.9 ± 9.88 | 43.5 ± 9.90 | 42.4 ± 10.77 | 42.6 ± 10.13 |
| Sex: Female, Male(Participants) | Lumateperone 14 mg (ITI-007 20 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Risperidone | Total |
|---|---|---|---|---|---|
| Female | 47 | 49 | 46 | 41 | 183 |
| Male | 125 | 123 | 132 | 132 | 512 |
| Race/Ethnicity, Customized(Participants) | Lumateperone 14 mg (ITI-007 20 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Risperidone | Total |
|---|---|---|---|---|---|
| White | 26 | 30 | 35 | 40 | 131 |
| Back or African American | 140 | 140 | 133 | 123 | 536 |
| Asian | 2 | 0 | 3 | 2 | 7 |
| Other | 4 | 2 | 7 | 8 | 21 |
| Positive and Negative Syndrome Scale (PANSS) Total Score(units on a scale) | Lumateperone 14 mg (ITI-007 20 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Risperidone | Total |
|---|---|---|---|---|---|
| Mean | 88.7 ± 9.86 | 90.9 ± 10.26 | 90.0 ± 9.81 | 90.0 ± 9.60 | 89.9 ± 9.89 |
The record gives a start of Jun 2015, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2025, 9 years 2 months after primary completion. A results delay was requested in Nov 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Intra-Cellular Therapies, Inc. →